e-learning
resources
Barcelona 2013
Wednesday, 11.09.2013
Progress in bronchoscopy and pathology techniques for diagnosis of thoracic malignancies
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
EGFR, KRAS, HER2, BRAF and PI3KCA mutation status in metastatic cancer patients: Thoracic cytological specimens obtained in routine clinical practice
T. Vandemoortele, I. Nanni-Metellus, E. Kaspi, V. Secq, S. Laroumagne, P. Roll, E. Roca, H. Dutau, A. Robaglia, P. Astoul (Marseille, France)
Source:
Annual Congress 2013 –Progress in bronchoscopy and pathology techniques for diagnosis of thoracic malignancies
Session:
Progress in bronchoscopy and pathology techniques for diagnosis of thoracic malignancies
Session type:
Poster Discussion
Number:
5092
Disease area:
Thoracic oncology
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
T. Vandemoortele, I. Nanni-Metellus, E. Kaspi, V. Secq, S. Laroumagne, P. Roll, E. Roca, H. Dutau, A. Robaglia, P. Astoul (Marseille, France). EGFR, KRAS, HER2, BRAF and PI3KCA mutation status in metastatic cancer patients: Thoracic cytological specimens obtained in routine clinical practice. Eur Respir J 2013; 42: Suppl. 57, 5092
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Emerging classes of drugs for the treatment of obstructive lung disease
Related content which might interest you:
A detailed immunohistochemical analysis of PI3K/AKT/MTOR pathway in lung cancer: Correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features
Source: Annual Congress 2013 –Prognostic factors and subtyping of lung cancer
Year: 2013
Cytological samples for the study of EGFR, KRAS and ALK mutations in non-small cell lung cancer
Source: Annual Congress 2013 –Progress in bronchoscopy and pathology techniques for diagnosis of thoracic malignancies
Year: 2013
Clinical characteristics of 32 patients with BRAF V600E-mutated lung adenocarcinoma
Source: International Congress 2015 – Advances in the therapy of lung cancer
Year: 2015
Lung adenocarcinoma with concomitant EGFR mutation and ALK rearrangement: Analysis of two cases and literature review
Source: International Congress 2016 – Basic science and case reports in lung cancer
Year: 2016
Prognostic value of TP53, KRAS and EGFR mutations in nonsmall cell lung cancer: the EUELC cohort
Source: Eur Respir J 2012; 40: 177-184
Year: 2012
EGFRmutations are associated with higher brain metastasis radio-sensitivity than KRAS mutations or wild type EGFR in non-small cell lung cancer patients (NSCLC)
Source: International Congress 2014 – Therapy of thoracic tumours: clinical trials and case series
Year: 2014
Validation of PNA-LNA PCR clamp assay for detection of EGFR exon 19 and 21 mutations in various types of clinical non-small cell lung cancer specimens
Source: Annual Congress 2013 –Translational research to bridge the need within clinical decision making
Year: 2013
Homozygous deletion of PTEN and poor outcomes in EGFR mutant NSCLC patients with gefitinib therapy
Source: International Congress 2015 – Lung cancer therapy: clinical trials
Year: 2015
Frequency and type of EGFR mutations in patients with adenocarcinoma of the lung
Source: Annual Congress 2013 –Prognostic factors and subtyping of lung cancer
Year: 2013
EGFR frequency and response to chemotherapy in a Brazilian NSCLC population
Source: Annual Congress 2013 –Systemic therapy of lung cancer and quality of life
Year: 2013
Is residential radon associated with mutations in drivers genes in never smokers lung cancer cases? The case of EGFR and ALK
Source: International Congress 2016 – Epidemiology and specific subgroups in lung cancer
Year: 2016
Allele-specific real-time PCR detection of EGFR exon 19 and 21 mutations in various clinical non-small cell lung cancer specimens
Source: International Congress 2014 – Basic and translational research in lung cancer and non-neoplastic pulmonary diseases
Year: 2014
EGFR, KRAS, BRAF and ALK gene alterations in lung adenocarcinomas: patient outcome, interplay with morphology and immunophenotype
Source: Eur Respir J 2014; 43: 872-883
Year: 2014
RT-PCR and IHC as the alternative methods for detection of ALK aberrations in NSCLC samples - The feasibility study
Source: International Congress 2015 – Promising novel findings in translational pulmonary research
Year: 2015
Feasibility of bronchoscopy obtained tissue for tumor diagnosis and testing epidermal growth factor receptor (EGFR) mutational status
Source: Annual Congress 2013 –Other thoracic tumours, particular circumstances and rare cases
Year: 2013
Unexpected hair growth induced by gefitinib treatment in two patients with EGFR gene mutation-positive adenocarcinoma of the lung
Source: International Congress 2015 – Diagnosis and therapy of lung cancer
Year: 2015
Noninvasive detection of
EGFR
T790M mutation in gefitinib resistant non-small cell lung cancer using mutant-enriched PCR
Source: Annual Congress 2013 –New methods for diagnostic workup of lung cancer
Year: 2013
EGFR mutations determine EGFR-MET crosstalk and MET inhibition in lung cancer
Source: International Congress 2015 – Biomarkers, immunology and molecular pathology of lung cancer
Year: 2015
The diagnosis and incidence of epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) mutation in lung adenocarcinoma
Source: International Congress 2015 – Lung cancer: prognostic factors and features of oncogene-driven tumours
Year: 2015
European mapping of EGFR mutation test and EGFR tyrosine kinase inhibitors availability in thoracic oncology
Source: International Congress 2015 – Quality management in lung cancer
Year: 2015
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept